Senators are pushing the bipartisan INSULIN Act of 2026, which would cap insulin costs at $35 a month for insured and ...
Advocates expect the young adult population to especially benefit from the bill, since many struggle to get high-quality ...
A bipartisan quartet of of senators on Wednesday unveiled legislation to cap the monthly cost of insulin at $35 for patients ...
5d
Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs
Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t ...
A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...
The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...
Read more from STAT contributor Brianna Abbott on the popular vote winner. And STAT’s Amanda Erickson, who edits this very newsletter, has a dispatch on the research our editors chose as the best ...
Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
Pharmaceutical Technology on MSN
Novo Nordisk receives FDA approval for basal insulin Awiqli
The FDA’s decision is based on data from the ONWARDS Phase IIIa clinical programme involving nearly 2,680 adults.
Capping Medicare beneficiaries’ monthly insulin out-of-pocket costs at $35 was associated with steep reductions in spending ...
The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results